Growth – Talk Bio

UK cuts 2026 new-medicine rebate rate to 14.5% under VPAG

5 days ago talkbio0Tagged branded medicines, clawback rate, Drug Industry, drug price, Growth, Nance-Horan syndrome, rebate rate, United Kingdom, valproic acid glucuronide, Voluntary Scheme

United Kingdom; VPAG; Voluntary Scheme for Branded Medicines Pricing Access and Growth; rebate rate; clawback rate; new medicines; NHS; drug pricing; pharmaceutical industry; 2026

Pharma Investment Surge in US Manufacturing Creates Major Opportunities for CDMOs

1 month ago talkbio0Tagged Advanced therapies, alpha 1-antitrypsin, Biological Factors, capital investment, CDMOs, eli lilly, Growth, Johnson & Johnson, Market, pharmaceutical manufacturing, production, supply chain, U.S.

US pharmaceutical manufacturing; CDMOs; capital investment; Johnson & Johnson; Eli Lilly; biologics; API production; supply chain; advanced therapies; market growth

More Than a Third of New Zepbound Prescriptions Driven by Lilly’s DTC Program

2 months ago talkbio0Tagged Direct-to-Consumer, discount, eli lilly, Glucagon-Like Peptide 1, Growth, LillyDirect, Market, Pricing, Sales - occupational activity, Sharing (Social Behavior), Walmart Pharmacy, Weight maintenance regimen, Zepbound

Zepbound; Eli Lilly; LillyDirect; direct-to-consumer; Walmart Pharmacy; GLP-1; weight management; discount pricing; market share; sales growth

Recent News: Gain Peace of Mind with the Lentiviral Experts

3 months ago talkbio0Tagged advanced manufacturing, Biological Factors, CAR-T therapy, gene therapy, Growth, immuno-oncology, lentiviral vectors, Market, regulatory approval

lentiviral vectors; CAR-T therapy; gene therapy; biologics; immuno-oncology; market growth; advanced manufacturing; regulatory approval

Recent News on Scaling Up Cell & Gene Therapy Supply Chains (2025)

3 months ago talkbio0Tagged Automation, Cells, digital solutions, gene therapy, Growth, Logistics, Market, patient-specific therapies, risk mitigation, scalability, supply chain, white glove delivery

cell and gene therapy; supply chain; scalability; logistics; digital solutions; risk mitigation; white glove delivery; patient-specific therapies; automation; market growth

Teva Execs Shrug Off Pharmaceutical Tariff Threat as Turnaround Strategy Rolls Forward

5 months ago talkbio0Tagged earnings, Francis, Growth, operating profit margin, pharmaceutical tariffs, Pivot Device, Richard, supply chain, tariff threat, Teva, turnaround strategy

Teva; tariff threat; pharmaceutical tariffs; turnaround strategy; supply chain; pivot to growth; earnings; innovative medicines; Richard Francis; operating profit margin

CDMO Pulse Check: Lonza Posts Major Sales Rebound as Samsung Bio Keeps Revenue Growth Rolling

5 months ago talkbio0Tagged capsule (pharmacologic), CDMO, commercial, expansion, Growth, Lonza, Manufacturing, profit margin, Sales - occupational activity, Samsung Bio

Lonza; CDMO; sales growth; Samsung Bio; 2025 outlook; profit margin; Capsules & Health Ingredients; commercial momentum; manufacturing expansion

Bristol Myers CEO: America’s Biopharma Leadership Not Guaranteed

7 months ago talkbio0Tagged Americas, Biopharma, CEO, Chris Boerner, dealmaking, global competitiveness, Growth, innovation, Myers, squibb

Bristol Myers Squibb; CEO; Chris Boerner; biopharma; Americas; global competitiveness; dealmaking; innovation; growth portfolio

Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

7 months ago talkbio0Tagged Azafaros, Brain-Penetrant Drug, Capital, Clinical Trials, Forbion, Growth, Jeito, Lysosomal Storage Diseases, neuro-metabolic diseases, Neurodegenerative Disorders, nizubaglustat, Phase 3, Series B funding

Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases

Pivotal readouts on deck as Takeda sees stagnant sales this year

7 months ago talkbio0Tagged Growth, JPY, Phase 3, Pivotal, Sales - occupational activity, Takeda

Takeda, Phase 3, Pivotal, Growth, Sales – occupational activity, JPY